EP0837066B1 - Verfahren zur herstellung von penicilling-phenylester - Google Patents

Verfahren zur herstellung von penicilling-phenylester Download PDF

Info

Publication number
EP0837066B1
EP0837066B1 EP96917662A EP96917662A EP0837066B1 EP 0837066 B1 EP0837066 B1 EP 0837066B1 EP 96917662 A EP96917662 A EP 96917662A EP 96917662 A EP96917662 A EP 96917662A EP 0837066 B1 EP0837066 B1 EP 0837066B1
Authority
EP
European Patent Office
Prior art keywords
salt
compound
mixture
penicillin
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP96917662A
Other languages
English (en)
French (fr)
Other versions
EP0837066A4 (de
EP0837066A1 (de
Inventor
Satoru Takahashi
Atsushi Yamamura
Hisashi Hayashida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Schering Plough Animal Health KK
Original Assignee
Takeda Schering Plough Animal Health KK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Schering Plough Animal Health KK filed Critical Takeda Schering Plough Animal Health KK
Publication of EP0837066A1 publication Critical patent/EP0837066A1/de
Publication of EP0837066A4 publication Critical patent/EP0837066A4/de
Application granted granted Critical
Publication of EP0837066B1 publication Critical patent/EP0837066B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/04—Preparation
    • C07D499/08—Modification of a carboxyl radical directly attached in position 2, e.g. esterification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D499/00—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring
    • C07D499/21—Heterocyclic compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. penicillins, penems; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulfur-containing hetero ring with a nitrogen atom directly attached in position 6 and a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
    • C07D499/44—Compounds with an amino radical acylated by carboxylic acids, attached in position 6

Definitions

  • This invention relates to a novel process for producing penicillin G phenyl esters. More particularly, this invention relates to a process for producing penicillin G phenyl esters advantageously on a commercial scale by way of intermediates which are novel compounds.
  • the objective compound (I) of this invention shows a very favorable absorption characteristic following oral administration when used as a therapeutic agent for enterococcicosis in fish, for instance, and the following route of synthesis is known for its production [PCT/JP92/01327)
  • the inventors of this invention explored for a safe and commercially advantageous production technology and discovered a safe and industrially useful process for producing penicillin G phenyl esters via the following intermediates (II) and (IIa) which are novel compounds.
  • the intermediate (II) described hereinafter particularly the following intermediate (IIa): has a small molecular mass offering the additional advantage that, process-wise, a smaller-capacity reactor suffices for the intermediate reaction step.
  • the objective compound (I) of the invention can be represented by the formula:
  • the objective compound (I) can be produced by acylating a compound of the formula: or a salt thereof to provide a compound of the formula: or a salt thereof and reacting it further with a compound of the formula: or a salt thereof to provide a compound of the formula: or a salt thereof.
  • the objective compound (I) can be produced by the following processes. or a salt thereof
  • the pharmaceutically acceptable salt of the objective compound (I) is preferably a nontoxic salt of the common kind, which includes various acid addition salts.
  • inorganic acid addition salts e.g. hydrochloride, hydrobromide, sulfate, phosphate, etc.
  • organic carboxylic or sulfonic acid addition salts e.g. formate, acetate, trifluoroacetate, oxalate, maleate, fumarate, tartrate, methanesulfonate, benzenesulfonate, p-toluenesulfonate, etc.
  • salts with acidic amino acids e.g. aspartate, glutamate, etc.
  • Compound (II) or a salt thereof can be produced by subjecting compound (III) or a salt thereof to selective acylation of its alcoholic hydroxyl group.
  • the preferred salt of compound (II) and of compound (III) includes salts with inorganic bases, such as alkali metal salts (e.g. sodium salt, potassium salt, cesium salt, etc.), alkaline earth metal salts (e.g calcium salt, magnesium salt, etc.), and ammonium salts; salts with organic bases, such as organic amine salts (e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexylamine salt, N,N'-dibenzylethylenediamine salt, etc.).
  • alkali metal salts e.g. sodium salt, potassium salt, cesium salt, etc.
  • alkaline earth metal salts e.g calcium salt, magnesium salt, etc.
  • ammonium salts e.g. trimethylamine salt, triethylamine salt, pyridine salt, picoline salt, ethanolamine salt, triethanolamine salt, dicyclohexy
  • the acylating agent which can be used for this acylation reaction includes the compound of the formula: or a salt thereof, or a reactive derivative thereof.
  • the preferred reactive derivative is an acid halide, although an acid anhydride may also be employed.
  • the preferred acid halide includes the acid chloride and acid bromide.
  • the preferred “acid anhydride” includes mixed anhydrides with alkanoic acids (e.g. the mixed anhydride with acetic acid) and those with alkenoic acids (e.g. the mixed anhydride with 2-butenoic acid) as well.
  • This reaction is generally conducted in the common solvent such as acetone, dioxane, tetrahydrofuran, diethyl ether, diisopropyl ether, acetonitrile, chloroform, methylene chloride, ethylene chloride, ethyl acetate, N,N-dimethylformamide, toluene, etc. or a mixture of such solvents, although the reaction may be optionally carried out in any other organic solvent that does not interfere with the reaction.
  • the common solvent such as acetone, dioxane, tetrahydrofuran, diethyl ether, diisopropyl ether, acetonitrile, chloroform, methylene chloride, ethylene chloride, ethyl acetate, N,N-dimethylformamide, toluene, etc. or a mixture of such solvents, although the reaction may be optionally carried out in any other organic solvent that does not interfere with the reaction.
  • reaction temperature there is no particular limitation on the reaction temperature but the reaction is generally carried out under cooling, at room temperature, or under warming.
  • the objective compound (I) or salt mentioned above can be produced by reacting compound (IV) or a salt thereof with compound (II) or a salt thereof.
  • the preferred salt of compound (IV) includes those corresponding to the above-mentioned salts of compound (II).
  • This reaction is generally carried out by the conventional esterification procedure, e.g. in the presence of a condensing agent which is routinely used, such as carbodiimides (e.g. N,N'-dicyclohexylcarbodiimide, N-cyclohexyl-N'-morpholinoethylcarbodiimide, N-cyclohexyl-N'-(4-diethylaminocyclohexyl)carbodiimide, N,N'-diethylcarbodiimide, N,N'-diisopropylcarbodiimide, N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide, etc.), triazoles (e.g.
  • halopyridinium salts e.g. 2-chloro-1-methylpyridinium iodide etc.
  • cyanuric chloride-pyridine complex e.g. 2-chloro-1-methylpyridinium iodide etc.
  • cyanuric chloride-pyridine complex e.g. 2-chloro-1-methylpyridinium iodide etc.
  • cyanuric chloride-pyridine complex e.g. 2-
  • Preferred among the above-mentioned condensing agents are cyanuric chloride-pyridine complex, thionyl chloride-dimethylformamide (Vilsmeier's reagent), and N,N'-dicyclohexylcarbodiimide.
  • This reaction is generally carried out in the presence of an inorganic or organic base such as alkali metal hydroxides (e.g. sodium hydroxide, potassium hydroxide, etc.), alkali metal carbonates (e.g. sodium carbonate, potassium carbonate, etc.), alkali metal hydrogen carbonates (e.g. sodium hydrogen carbonate, potassium hydrogen carbonate, etc.), tri(lower)alkylamines (e.g. trimethylamine, triethylamine, etc.), pyridine and its derivatives (e.g. picoline, lutidine, 4-dimethylaminopyridine, etc.), N-(lower)alkylmorpholine, and N,N-di(lower)alkylbenzylamine, among other bases.
  • alkali metal hydroxides e.g. sodium hydroxide, potassium hydroxide, etc.
  • alkali metal carbonates e.g. sodium carbonate, potassium carbonate, etc.
  • alkali metal hydrogen carbonates e.g. sodium
  • This reaction is generally conducted in the common solvent such as dioxane, tetrahydrofuran, diethyl ether, diisopropyl ether, acetonitrile, chloroform, methylene chloride, ethylene chloride, ethyl acetate, N,N-dimethylformamide, etc. or using any desired organic solvent that does not interfere with the reaction.
  • the common solvent such as dioxane, tetrahydrofuran, diethyl ether, diisopropyl ether, acetonitrile, chloroform, methylene chloride, ethylene chloride, ethyl acetate, N,N-dimethylformamide, etc. or using any desired organic solvent that does not interfere with the reaction.
  • the condensing agent or the base, which is liquid, can be used as the solvent as well.
  • reaction temperature there is no particular limitation on the reaction temperature but the reaction is generally carried out under cooling, at room temperature, or under heating.
  • the compound obtained by the above process can be isolated and purified by routine procedures such as, for example, extraction, precipitation, fractional crystallization, recrystallization, distillation under reduced pressure, and chromatography.
  • the present invention provides a production technology for penicillin G phenyl ester (I) which is superior to the prior art technology in both safety and amenability to commercial-scale production.
  • the process of this invention has the following advantages over the prior art process.
  • the intermediate (B) used in the prior art process does not crystallize but is only available as an oil and its purification has to depend on silica gel column chromatography which is not suited for commercial production.
  • the intermediate (D) for use in the process of this invention although it is oily, too, can be easily purified by distillation under reduced pressure (b.p. 150°C/0.4 Torr).
  • the process of this invention is superior to the prior art process in yield, operability, and economics (the intermediates (E) and (D) in the process of this invention are low molecular weight compounds as compared with the intermediates (B) and (C) in the prior art process and, therefore, the volume of the reaction system is smaller on an equimolar reaction basis).
  • 3-Hydroxybenzaldehyde (20.1 g) is suspended in water (41 ml). To this suspension is added sodium borohydride (1.65 g) in a nitrogen atmosphere at 20-30°C, and the mixture is stirred for 30 minutes. At a temperature not exceeding 20°C, concentrated hydrochloric acid (about 2.5 ml) is added gradually to adjust the mixture to pH 7. To this mixture, ethyl acetate (41 ml) and sodium chloride (11.5 g) are added for extraction. The organic layer is separated, dried over anhydrous magnesium sulfate (10 g), and concentrated under reduced pressure to 30 ml. To this residue is added 205 ml of n-heptane for crystallization. The resulting crystals are recovered by filtration and dried in vacuo to provide white crystals of 3-hydroxybenzyl alcohol (20.2 g; yield 99%).
  • Penicillin G potassium (10.0 g) is suspended in pyridine (50 ml), and in a nitrogen atmosphere at 20 ⁇ -10°C, a solution of cyanuric chloride (5.71 g) in tetrahydrofuran (40 ml) is added dropwise. Then, at the same temperature, 3-hydroxybenzaldehyde (2.76 g) is added dropwise and washed in with tetrahydrofuran (10 ml). The mixture is stirred at -5° - 0°C for 2.5 hours, at the end of which time ethyl acetate (100 ml) and water (150 ml) are added.
  • a mixture of penicillin G potassium (60.0 g) and pyridine (29.7 g) is added dropwise with stirring in a nitrogen atmosphere at -10° ⁇ -20°C. Then, at the same temperature, 3-isobutyryloxymethylphenol (26.0 g) is added dropwise. After completion of dropwise addition, the mixture is further stirred at -20° ⁇ 0°C for 1 hour.
  • This reaction mixture is diluted with water (400 ml) and ethyl acetate (350 ml) and then adjusted to pH3 with dilute HCl for extraction. The organic layer is separated, washed with saturated aqueous solution of sodium hydrogen carbonate twice, dried over anhydrous sodium sulfate, and concentrated.
  • the filtrate is concentrated under reduced pressure and the residue is distributed using water (70 ml) and ethyl acetate (70 ml).
  • the ethyl acetate layer is separated, dried over anhydrous sodium sulfate, and concentrated under reduced pressure.
  • the physical constants of this compound are in agreement with those of the compound synthesized in Example 4.
  • a suspension of penicillin G potassium salt (4.60 g) in methylene chloride (18 ml) is cooled to a temperature not exceeding -5°C and N-methylmorpholine (1.2 ml) and methanesulfonyl chloride (1.4 ml) are added in that order at -5°C with constant stirring.
  • the mixture is further stirred at a temperature not over 0°C for 90 minutes.
  • 3-isobutyryloxymethylphenol (2.21 g) is added dropwise at 0° ⁇ -5°C.
  • the drip funnel is washed with methylene chloride (4 ml) and the washes are added to the reaction mixture. The mixture is then stirred at 0° ⁇ -5°C for 2 hours.
  • This reaction mixture is diluted with water (14 ml) and the organic layer is separated, washed serially with 5% citric acid, 25% aqueous NaCl, 10% aqueous NaHCO 3 , 25% aqueous NaCl, and water (14 ml each), dried over anhydrous magnesium sulfate, and finally concentrated to dryness under reduced pressure.
  • the resulting crude crystals are dissolved in ethyl acetate (9 ml), and n-heptane (46 ml) is added dropwise for crystallization.
  • the crystal crop is harvested by filtration and dried in vacuo to provide penicillin G 3-isobutyryloxymethylphenyl ester as white crystals (2.63 g).
  • the physical constants of the compound thus obtained are in greement with those of the compound synthesized in Example 4.
  • thionyl chloride (7.35 g) at a temperature not exceeding 0°C and the mixture is stirred well. The stirring is further continued at a temperature not over 0°C, and penicillin G potassium (21.10 g), 3-isobutyryloxymethylphenol (10.94 g), and pyridine (9.76 g) are added in the order mentioned. The mixture is then stirred at -10° ⁇ 0°C for 30 minutes, after which ethyl acetate (100 ml) and 20% aqueous NaCl solution (100 ml) are serially added.
  • the organic layer was separated and washed with 20% NaCl, 10% citric acid-20% NaCl (1:1), 5% NaHCO 3 -20% NaCl (1:1), and 20% NaCl (100 ml each) in the order mentioned.
  • the organic layer is separated and concentrated under reduced pressure and the residual oil is dissolved in isopropyl alcohol (100 ml). While this solution is stirred at 20°-25°C, seed crystals are added and water (150 ml) is then added dropwise for crystallization. The resulting crystals are collected by filtration and dried in vacuo to provide penicillin G 3-isobutyryloxymethylphenyl ester (24.3 g).
  • the physical constants of the compound thus obtained are in agreement with those of the compound synthesized in Example 4.
  • a mixture of cyanuric chloride (3.70 g) and ethyl acetate (54 ml) is cooled to -10° ⁇ -5°C.
  • pyridine (7.94 g) is added dropwise with stirring at the same temperature.
  • dimethylformamide (27 ml), penicillin G potassium salt (6.90 g) and 3-isobutyryloxymethylphenol (3.0 g) are added in that order and the mixture is stirred at -10° ⁇ -5°C for 5 hours.
  • the reaction mixture is washed twice with 5% citric acid and 10% aqueous NaCl (60 ml each) and once with 2.5% aqueous NaHCO 3 , 10% aqueous NaCl, and water (60 ml each).
  • the organic layer is concentrated to dryness under reduced pressure and the residue is dissolved in isopropyl alcohol (30 ml) at 20°-25°C.
  • the mixture is stirred for 30 minutes, after which water (45 ml) is added dropwise for crystallization.
  • the crystals are collected by filtration and dried to provide penicillin G 3-isobutyryloxymethylphenyl ester (6.95 g) as white crystals.
  • the physical constants of this compound are in agreement with those of the compound synthesized in Example 4.
  • This reaction mixture is diluted with ethyl acetate (20 l) and washed once with water (30 l), twice with a cooled dilute HCl/aqueous NaCl solution (22 l) twice with 10% aqueous NaHCO 3 solution (10 l), and once with saturated aqueous NaCl solution (10 l) in the order mentioned.
  • the organic layer is dried (over MgSO 4 ) and filtered with the aid of activated carbon.
  • the filtrate is concentrated under reduced pressure to about 4l and N-hexane (22 l) is added to the residue for crystallization.
  • the crystals are collected by filtration to provide penicillin G 3-isobutyryloxymethylphenyl ester (2.0 kg) as white crystals.
  • the physical constants of this compound are in agreement with those of the compound synthesized in Example 4.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cephalosporin Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Claims (6)

  1. Verfahren zur Herstellung eines Penicillin-G-Phenylesters der Formel
    Figure 00240001
    oder eines Salzes davon, welches Umsetzung einer Verbindung der Formel
    Figure 00240002
    oder eines Salzes davon mit einer Verbindung der Formel
    Figure 00240003
    oder einem Salz davon umfasst.
  2. Verfahren nach Anspruch 1, wobei die Reaktion in Gegenwart eines Kondensationsmittels durchgeführt wird.
  3. Verfahren zur Herstellung eines Peniclllln-G-Phenylesters der Formel
    Figure 00250001
    oder eines Salzes davon, welches Acylieren einer Verbindung der Formel
    Figure 00250002
    oder eines Salzes davon zur Herstellung einer Verbindung der Formel
    Figure 00250003
    oder eines Salzes davon und Umsetzung desselben mit einer Verbindung der Formel
    Figure 00250004
    oder einem Salz davon umfosst.
  4. Verfahren zur Herstellung eines Penicillin-G-Phenylesters der Formel
    Figure 00260001
    oder eines Salzes davon, welches Acylieren einer Verbindung der Formel
    Figure 00260002
    oder eines Salzes davon zur Herstellung einer Verbindung der Formel
    Figure 00260003
    oder eines Salzes davon und Umsetzung derselben mit einer Verbindung der Formel
    Figure 00260004
    oder einem Salz davon umfasst.
  5. Verbindung der Formel
    Figure 00270001
    oder ein Salz davon.
  6. Verbindung der Formel
    Figure 00270002
    oder ein Salz davon.
EP96917662A 1995-06-14 1996-06-13 Verfahren zur herstellung von penicilling-phenylester Expired - Lifetime EP0837066B1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP14752895 1995-06-14
JP147528/95 1995-06-14
JP14752895 1995-06-14
JP8078296 1996-03-07
JP80782/96 1996-03-07
JP8078296 1996-03-07
PCT/JP1996/001604 WO1997000259A1 (fr) 1995-06-14 1996-06-13 Procede ameliore de production de phenyl-ester de penicilline g

Publications (3)

Publication Number Publication Date
EP0837066A1 EP0837066A1 (de) 1998-04-22
EP0837066A4 EP0837066A4 (de) 1998-11-25
EP0837066B1 true EP0837066B1 (de) 2003-09-03

Family

ID=26421757

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96917662A Expired - Lifetime EP0837066B1 (de) 1995-06-14 1996-06-13 Verfahren zur herstellung von penicilling-phenylester

Country Status (10)

Country Link
EP (1) EP0837066B1 (de)
JP (1) JP3377795B2 (de)
KR (1) KR100402595B1 (de)
CN (1) CN1092661C (de)
AT (1) ATE248841T1 (de)
DE (1) DE69629815T2 (de)
DK (1) DK0837066T3 (de)
ES (1) ES2205034T3 (de)
PT (1) PT837066E (de)
WO (1) WO1997000259A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5419119B2 (ja) * 2007-08-20 2014-02-19 国立大学法人名古屋大学 エステルの製造法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD150393A3 (de) * 1978-04-05 1981-09-02 Wolfgang Krueger Verfahren zur herstellung halbsynthetischer penicilline und ihrer alkalisalze
US5112967A (en) * 1990-04-27 1992-05-12 Hoffmann-La Roches Inc. Process for synthesizing antibacterial cephalosporin compounds
JP2952015B2 (ja) * 1990-08-28 1999-09-20 大塚化学株式会社 ペニシリン類のエステル化方法
WO1993008196A1 (en) * 1991-10-15 1993-04-29 Fujisawa Pharmaceutical Co., Ltd. Penicillin g ester

Also Published As

Publication number Publication date
ATE248841T1 (de) 2003-09-15
DK0837066T3 (da) 2003-11-24
ES2205034T3 (es) 2004-05-01
CN1187822A (zh) 1998-07-15
EP0837066A4 (de) 1998-11-25
DE69629815T2 (de) 2004-04-08
JP3377795B2 (ja) 2003-02-17
WO1997000259A1 (fr) 1997-01-03
EP0837066A1 (de) 1998-04-22
PT837066E (pt) 2004-01-30
KR100402595B1 (ko) 2005-09-02
CN1092661C (zh) 2002-10-16
DE69629815D1 (de) 2003-10-09
KR19990014793A (ko) 1999-02-25

Similar Documents

Publication Publication Date Title
US3963702A (en) Phthalide penicillin ester intermediates
KR940006764B1 (ko) (z)-1-페닐-1-디에틸아미노카르보닐-2-아미노메틸싸이클로프로판 염산염의 제조방법
SU965356A3 (ru) Способ получени производных /эрголинил/-N,N-диэтилмочевины или их солей
JP2691442B2 (ja) 新規なプロリン誘導体
SU474980A3 (ru) Способ получени (1-п-хлорбензоил-5-метокси-2-метил-3-индол) ацетоксиуксусной кислоты или ее солей
JP2005521634A (ja) レパグリニドの製法
KR880001847B1 (ko) 새로운 베타-락탐초산유도체의 제조방법
EP0837066B1 (de) Verfahren zur herstellung von penicilling-phenylester
EP0018546B1 (de) Verfahren zur Herstellung von Phenylglycyl-chlorid-hydrochloriden
US6835829B2 (en) Purification process
EP1173444B1 (de) Kristalline beta-lactam intermediate
WO2002068428A1 (en) Method of preparing cephalosporins using 4-hydroxyphenylglycine derivatives
US5288860A (en) Process for preparing thiazolino azetidinone and 2-exo-methylenepenam derivative
JP3207017B2 (ja) ベンジルコハク酸誘導体の製造方法およびその製造中間体
EP0643047A1 (de) 1(2-Amino-5(1-(Triphenylmethyl-1H-Imidazol-4-Yl)-1-Oxopentyl)Piperidin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Synthesezwischenprodukte
US5977380A (en) Process for preparing N-[1- (S)-ethoxycarbonyl-3- phenylpropyl]-L-alanine derivatives
JP2001521498A (ja) Ｏ−（３−アミノ−２−ヒドロキシ−プロピル）−ヒドロキシミック酸ハロゲン化物の製造方法
JPS62174082A (ja) ７−（２−アジドメチルフエニルアセトアミド）−セフアロスポリン化合物
US4123611A (en) N-protected amino compounds
US4029647A (en) Synthesis of biotin
JP3241741B2 (ja) 「３−（７−アミジノ−２−ナフチル）−２−フェニルプロピオン酸誘導体の製造方法」
US4179557A (en) Acylation of 7-aminocephalosporanic acids
JPH069553A (ja) １−［｜２ｓ｜−メチル−３−メルカプトプロピオニル−ピロリジン−｜２ｓ｜−カルボン酸の製法
JPH03141253A (ja) モノバクテーム及びそれらの中間体生成物の調製方法
JPH1087586A (ja) 鏡像異性的に純粋なシクロペンタン−β−アミノ酸の調製のための新規な効率的で高度にエナンチオ選択的な方法

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971216

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 19981009

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20000626

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: TAKEDA SCHERING-PLOUGH ANIMAL HEALTH K.K.

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: CH

Ref legal event code: NV

REF Corresponds to:

Ref document number: 69629815

Country of ref document: DE

Date of ref document: 20031009

Kind code of ref document: P

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DK

Ref legal event code: T3

REG Reference to a national code

Ref country code: SE

Ref legal event code: TRGR

REG Reference to a national code

Ref country code: GR

Ref legal event code: EP

Ref document number: 20030404566

Country of ref document: GR

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2205034

Country of ref document: ES

Kind code of ref document: T3

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20040604

REG Reference to a national code

Ref country code: CH

Ref legal event code: PFA

Owner name: TAKEDA SCHERING-PLOUGH ANIMAL HEALTH K.K.

Free format text: TAKEDA SCHERING-PLOUGH ANIMAL HEALTH K.K.#3-7, HIRANOMACHI 2-CHOME, CHUO-KU#OSAKA 541-0046 (JP) -TRANSFER TO- TAKEDA SCHERING-PLOUGH ANIMAL HEALTH K.K.#3-7, HIRANOMACHI 2-CHOME, CHUO-KU#OSAKA 541-0046 (JP)

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: LU

Payment date: 20080624

Year of fee payment: 13

Ref country code: ES

Payment date: 20080609

Year of fee payment: 13

Ref country code: DK

Payment date: 20080606

Year of fee payment: 13

Ref country code: CH

Payment date: 20080625

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: AT

Payment date: 20080604

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: PT

Payment date: 20080526

Year of fee payment: 13

Ref country code: FI

Payment date: 20080604

Year of fee payment: 13

Ref country code: BE

Payment date: 20080602

Year of fee payment: 13

Ref country code: IT

Payment date: 20080626

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: SE

Payment date: 20080611

Year of fee payment: 13

Ref country code: NL

Payment date: 20080626

Year of fee payment: 13

Ref country code: IE

Payment date: 20080526

Year of fee payment: 13

Ref country code: DE

Payment date: 20080819

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20080529

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20080618

Year of fee payment: 13

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GR

Payment date: 20080527

Year of fee payment: 13

REG Reference to a national code

Ref country code: PT

Ref legal event code: MM4A

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20091214

BERE Be: lapsed

Owner name: *TAKEDA SCHERING-PLOUGH ANIMAL HEALTH K.K.

Effective date: 20090630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090613

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: DK

Ref legal event code: EBP

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20090613

NLV4 Nl: lapsed or anulled due to non-payment of the annual fee

Effective date: 20100101

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20100226

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20091214

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090615

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100101

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

Ref country code: AT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100101

Ref country code: DK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090630

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20090615

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100107

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090615

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090613

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090614